ArticleEuropean radiology2022
MRI grading for the prediction of prostate cancer aggressiveness.
Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Preoperative prediction of positive surgical margins in prostate cancer using multimodal deep learning model: a multicenter study.Abdominal radiology (New York) · 2026Article
- Deep learning based on multiparametric MRI for differentiating benign from malignant PI-RADS 3 prostate lesions: a dual-center study.Scientific reports · 2026Article
- Diagnostic value of prostate magnetic resonance imaging in men with prostate-specific antigen levels ≥ 15 ng/mL for biopsy decision-making.Insights into imaging · 2026Article
- The Impact of Endpoint Definitions on Predictors of Progression in Active Surveillance for Early Prostate Cancer.Cancers · 2026Article
- A novel MRI-based habitat analysis and deep learning for predicting perineural invasion in prostate cancer: a two-center study.BMC cancer · 2025Article
- [Active surveillance of prostate cancer].Urologie (Heidelberg, Germany) · 2025Review
- Positive MRI and ISUP GG1 on initial prostate biopsy? Reassessing baseline MRI is key.European radiology · 2025Article
- MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.European radiology · 2025Article
- Squared diffusion-weighted imaging for improving the detection of clinically significant prostate cancer.Scientific reports · 2025Article
- Diagnostic value ofCancer biology & therapy · 2024Article
- Multiparametric MRI for characterization of the tumour microenvironment.Nature reviews. Clinical oncology · 2024Review
- Histogram analysis of MR quantitative parameters: are they correlated with prognostic factors in prostate cancer?Abdominal radiology (New York) · 2024Article
- Improved diagnostic accuracy of readout-segmented echo-planar imaging for peripheral zone clinically significant prostate cancer: a retrospective 3T MRI study.Scientific reports · 2024Article
- MRI characteristics and oncological follow-up of patients with ISUP grade group 4 or 5 prostate cancer.Abdominal radiology (New York) · 2024Article
- Deep learning-based radiomics model from pretreatment ADC to predict biochemical recurrence in advanced prostate cancer.Frontiers in oncology · 2024Article
- Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies.BMC medical imaging · 2023Article
- Relationship between Proclarix and the Aggressiveness of Prostate Cancer.Molecular diagnosis & therapy · 2023Article
- Study of iron metabolism based on T2* mapping sequences in PI-RADS 3 prostate lesions.Frontiers in oncology · 2023Article
- Diffusion weighted imaging and diffusion kurtosis imaging in abdominal oncological setting: why and when.Infectious agents and cancer · 2022Review
- Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesT o evaluate the value of multiparametric MRI (mpMRI) for the prediction of prostate cancer (PCA) aggressiveness.
methodsIn this single center cohort study, consecutive patients with histologically confirmed PCA were retrospectively enrolled. Four different ISUP grade groups (1, 2, 3, 4-5) were defined and fifty patients per group were included. Several clinical (age, PSA, PSAD, percentage of PCA infiltration) and mpMRI parameters (ADC value, signal increase on high b-value images, diameter, extraprostatic extension [EPE], cross-zonal growth) were evaluated and correlated within the four groups. Based on combined descriptors, MRI grading groups (mG1-mG3) were defined to predict PCA aggressiveness.
resultsIn total, 200 patients (mean age 68 years, median PSA value 8.1 ng/ml) were analyzed. Between the four groups, statistically significant differences could be shown for age, PSA, PSAD, and for MRI parameters cross-zonal growth, high b-value signal increase, EPE, and ADC (p < 0.01). All examined parameters revealed a significant correlation with the histopathologic biopsy ISUP grade groups (p < 0.01), except PCA diameter (p = 0.09). A mixed linear model demonstrated the strongest prediction of the respective ISUP grade group for the MRI grading system (p < 0.01) compared to single parameters.
conclusionsMpMRI yields relevant pre-biopsy information about PCA aggressiveness. A combination of quantitative and qualitative parameters (MRI grading groups) provided the best prediction of the biopsy ISUP grade group and may improve clinical pathway and treatment planning, adding useful information beyond PI-RADS assessment category. Due to the high prevalence of higher grade PCA in patients within mG3, an early re-biopsy seems indicated in cases of negative or post-biopsy low-grade PCA. KEY POINTS: • MpMRI yields relevant pre-biopsy information about prostate cancer aggressiveness. • MRI grading in addition to PI-RADS classification seems to be helpful for a size independent early prediction of clinically significant PCA. • MRI grading groups may help urologists in clinical pathway and treatment planning, especially when to consider an early re-biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.